ArticleActas espanolas de psiquiatria2025
Correlation Between Serum Amisulpride Concentration, Therapeutic Efficacy, and Glycolipid Metabolism in the Treatment of Adult Female Schizophrenia.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmisulpride is a novel atypical antipsychotic (AAP) with slower absorption, metabolism, and excretion in females, potentially leading to elevated plasma concentrations. This study aimed to explore the correlation between serum amisulpride levels and therapeutic efficacy, glycolipid metabolism and side effects in adult female patients with schizophrenia (SCH).
methodsA retrospective study was conducted involving 122 adult female SCH patients admitted to the Third People's Hospital of Yongkang between January 2020 and January 2022. Fasting venous blood samples were collected at baseline and 1, 2, 4 and 8 weeks post-treatment with amisulpride. Key parameters measured included serum amisulpride concentration, Brief Psychiatric Rating Scale (BPRS) scores, fasting blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and side effect scores.
resultsSerum amisulpride levels significantly increased at 2, 4, and 8 weeks compared to the first week (p < 0.05), while BPRS scores significantly decreased at all time points compared to those before treatment (p < 0.05). A strong negative correlation was observed between amisulpride concentration and BPRS scores (r = -0.948, p < 0.001). Significant alterations in fasting blood glucose, TC, TG, HDL, and LDL levels were observed post-treatment (p < 0.05). Serum amisulpride concentration negatively correlated with fasting blood glucose, TC, and LDL (r = -0.622, -0.160, -0.796, respectively, p < 0.001) and positively correlated with TG (r = 0.447, p < 0.001). Side effects scores increased significantly after 2, 4, and 8 weeks compared to the first week (p < 0.05), with amisulpride concentration positively correlating with side effects scores (r = 0.739, p < 0.001).
conclusionSerum amisulpride levels in female SCH patients are closely correlated with therapeutic efficacy, glycolipid metabolism and incidence of side effects, respectively. Monitoring serum concentrations may provide valuable insights for guiding personalized medication management and optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.